Company Seeks Sale And Manufacturing Approval For Successful Stem Cell Parkinson’s Treatment

Company Seeks Sale And Manufacturing Approval For Successful Stem Cell Parkinson’s Treatment
Company Seeks Sale And Manufacturing Approval For Successful Stem Cell Parkinson’s Treatment Muhammad Ali and Michael J Fox, two of the most famous Parkinson’s patients, prepare to speak to the Senate – public domain For 10 million worldwide patients with Parkinson’s disease, news out of Japan that a large pharmaceutical corporation is seeking approval for a new stem cell-based treatment should be hugely encouraging. Following a successful clinical trial in which seniors between 50 and 59 years of age received injections of induced pluripotent stem cells (iPS) and saw either a halting or reversal in symptoms, Sumitomo Pharma have applied for manufacturing and marketing authorizations in Japan and the United States. Parkinson’s is a debilitating neurodegenerative disease characterized by a progressive loss of dopamine producing cells that results in a loss of motor functions. The clinical trial was led by Kyoto University, and the published results in Nature showed that 4 out of 7 patients …